Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin

Erythropoietin: Elucidating new cellular targets that broaden therapeutic strategies

“…Left ventricular ejection improved, stroke volume increased Goldberg et al, 1992, Silverberg et al, 2001 Cancer Treatment Synergy Improve efficacy of chemotherapy Ning et al, 2005;Sigounas et Bullard et al, 2005;Menon et al, 2006a; Mitochondrial Permeability and Caspases Chong et al, 2002b;2003e, Sharples et al, 2004Li et al, 2007a;Okutan et al, 2007;Wu et al, 2007a EPO and Akt, Forkhead Transcription Factors Akt Chong et al, 2002b;2003e;Parsa et al, 2003;Bahlmann et al, 2004;Sharples et al, 2004Miki et al, 2006;Um and Lodish, et al, 2006;Um et al, 2007;Wu et al, 2007b FOXO3a Chong and EPO and Wnt, GSK-3β, NF-κB Wnt Chong et al, 2007c Glycogen Synthase Kinase (GSK)-3β Li et al, 2006b;Chong et al, 2007c;Wu et al, 2007aNuclear Factor (NF)-κB Bittorf et al, 2001Chong et al, 2005d;Li et al, 2006b;Spandou et al, 2006 …”

“…For example, in patients with anemia EPO administration can increase left ventricular ejection fraction and stroke volume (Goldberg et al, 1992). This work has been followed by randomized control studies with EPO administration in patients with congestive heart failure or diabetes combined with congestive heart failure that demonstrate improved cardiac output and a decrease in medical resource utilization (Silverberg et al, 2003).…”

“…At present, there are at least 100 trials with the National Institutes of Health website (clinicaltrials.gov) that are either recruiting or in preparation to examine the clinical effects of EPO in patients with a variety of disorders that include anemia, cancer, cardiac ischemia, or spinal cord trauma. Although some cardiac injury experimental models do not consistently demonstrate a benefit with EPO (Olea et al, 2006), initial studies in patients with anemia or on chronic hemodialysis have suggested a direct cardiac benefit from EPO administration (Goldberg et al, 1992;Silverberg et al, 2001) (Table 1). Subsequent work has demonstrated that EPO administration can improve exercise tolerance either during cardiac or renal insufficiency in patients with anemia and congestive heart failure (Mancini et al, 2003;Palazzuoli et al, 2006) and that this may be tied to improved pulmonary function (Wu et al, 2006).…”

Erythropoietin and Oxidative Stress

“…Even in acute scenarios following coronary artery ligation, EPO leads to a decrease in apoptotic cells by fifty percent in the myocardium and significantly improves cardiac function (Moon, et al, 2003, Parsa, et al, 2003. Although some cardiac injury experimental models do not consistently demonstrate a benefit with EPO (Olea, et al, 2006), initial studies in patients with anemia or on chronic hemodialysis have suggested a direct cardiac benefit from EPO administration (Goldberg, et al, 1992, Silverberg, et al, 2001. Randomized control studies with EPO administration in patients with congestive heart failure or diabetes combined with congestive heart failure also demonstrate an improved cardiac output and a decrease in medical resource utilization .…”

Triple play: Promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus

“…For example, in patients with anemia, EPO administration can increase left ventricular ejection fraction and stroke volume [246]. More recent studies have shown that patients with acute myocardial infarction have increased plasma EPO levels within seven days of a cardiac insult, suggesting a possible protective response from the body [247].…”